BrdU does not induce hepatocellular damage in experimental Wistar rats

Acta Histochem. 2024 Jan;126(1):152117. doi: 10.1016/j.acthis.2023.152117. Epub 2023 Nov 27.

Abstract

Bromodeoxyuridine (BrdU) is used in studies related to cell proliferation and neurogenesis. The multiple intraperitoneal injections of this molecule could favor liver function profile changes. In this study, we evaluate the systemic and hepatocellular impact of BrdU in male adult Wistar rats in 30 %-partial hepatectomy (PHx) model. The rats received BrdU 50 mg/Kg by intraperitoneal injection at 0.5, 1, 2, 3, 6, 9 and 16 days after 30 %-PH. The rats were distributed into four groups as follows, control, sham, PHx/BrdU(-) and PHx/BrdU(+). On day 16, we evaluated hepatocellular nuclei and analyzed histopathological features by haematoxylin-eosin stain and apoptotic profile was qualified by caspase-3 presence. The systemic effect was evaluated by liver markers such as alanine transferase (ALT), aspartate aminotransferase (AST), lactate dehydrogenase (LDH), alkaline phosphatase (AP), bilirubin, total proteins and serum albumin content. The statistical analysis consisted of a student t-test and one-way ANOVA. BrdU did not induce apoptosis or hepatocellular damage in male rats. Multiple administrations of BrdU in male rats did not induce significant decrease body weight, but increased serum ALT and LDH levels were found. Our results show that the BrdU does not produce hepatocellular damage.

Keywords: Adult rats; Cell death; Hepatocellular damage; Intraperitoneal; Liver function.

MeSH terms

  • Alanine Transaminase / metabolism
  • Alanine Transaminase / pharmacology
  • Animals
  • Aspartate Aminotransferases / metabolism
  • Aspartate Aminotransferases / pharmacology
  • Bromodeoxyuridine / pharmacology
  • Carcinoma, Hepatocellular* / pathology
  • Liver / pathology
  • Liver Neoplasms* / pathology
  • Male
  • Rats
  • Rats, Wistar

Substances

  • Bromodeoxyuridine
  • Alanine Transaminase
  • Aspartate Aminotransferases